-
1
-
-
60149110364
-
-
US Renal Data System, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
-
US Renal Data System. USRDS 2008 Annual Data Report (2008), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
-
(2008)
USRDS 2008 Annual Data Report
-
-
-
2
-
-
20844462717
-
Effect of pravastatin on cardiovascular events in people with chronic kidney disease
-
Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 12 (2004) 1557-1563
-
(2004)
Circulation
, vol.110
, Issue.12
, pp. 1557-1563
-
-
Tonelli, M.1
Isles, C.2
Curhan, G.C.3
-
3
-
-
63649095045
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
-
JUPITER Trial Study Group
-
Ridker P.M., Danielson E., Fonseca F.A., et al., JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 9670 (2009) 1175-1182
-
(2009)
Lancet
, vol.373
, Issue.9670
, pp. 1175-1182
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
4
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
JUPITER Study Group
-
Ridker P.M., Danielson E., Fonseca F.A., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 21 (2008) 2195-2207
-
(2008)
N Engl J Med
, vol.359
, Issue.21
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
5
-
-
1642277853
-
C-Reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany
-
Koenig W., Lowel H., Baumert J., and Meisinger C. C-Reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 11 (2004) 1349-1353
-
(2004)
Circulation
, vol.109
, Issue.11
, pp. 1349-1353
-
-
Koenig, W.1
Lowel, H.2
Baumert, J.3
Meisinger, C.4
-
6
-
-
11344279659
-
C-Reactive protein levels and outcomes after statin therapy
-
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators
-
Ridker P.M., Cannon C.P., Morrow D., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 352 1 (2005) 20-28
-
(2005)
N Engl J Med
, vol.352
, Issue.1
, pp. 20-28
-
-
Ridker, P.M.1
Cannon, C.P.2
Morrow, D.3
-
7
-
-
63849163945
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
-
AURORA Study Group
-
Fellstrom B.C., Jardine A.G., Schmieder R.E., et al., AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 14 (2009) 1395-1407
-
(2009)
N Engl J Med
, vol.360
, Issue.14
, pp. 1395-1407
-
-
Fellstrom, B.C.1
Jardine, A.G.2
Schmieder, R.E.3
-
8
-
-
0036147221
-
HMG-Co A reductase inhibitors are associated with reduced mortality in ESRD patients
-
Seliger S.L., Weiss N.S., Gillen D.L., et al. HMG-Co A reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61 1 (2002) 297-304
-
(2002)
Kidney Int
, vol.61
, Issue.1
, pp. 297-304
-
-
Seliger, S.L.1
Weiss, N.S.2
Gillen, D.L.3
-
9
-
-
19944366583
-
HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients
-
Mason N.A., Bailie G.R., Satayathum S., et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45 1 (2005) 119-126
-
(2005)
Am J Kidney Dis
, vol.45
, Issue.1
, pp. 119-126
-
-
Mason, N.A.1
Bailie, G.R.2
Satayathum, S.3
-
10
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 3 (2005) 238-248
-
(2005)
N Engl J Med
, vol.353
, Issue.3
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
März, W.3
-
11
-
-
56549092147
-
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis
-
Krane V., Winkler K., Drechsler C., Lilienthal J., Marz W., and Wanner C. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74 11 (2008) 1461-1467
-
(2008)
Kidney Int
, vol.74
, Issue.11
, pp. 1461-1467
-
-
Krane, V.1
Winkler, K.2
Drechsler, C.3
Lilienthal, J.4
Marz, W.5
Wanner, C.6
-
12
-
-
38049033935
-
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis
-
Cholesterol Treatment Trialists' (CTT) Collaborators
-
Kearney P.M., Blackwell L., Collins R., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 9607 (2008) 117-125
-
(2008)
Lancet
, vol.371
, Issue.9607
, pp. 117-125
-
-
Kearney, P.M.1
Blackwell, L.2
Collins, R.3
-
13
-
-
64749106205
-
Statin effects in CKD: is there a "point of no return"?
-
Wanner C. Statin effects in CKD: is there a "point of no return"?. Am J Kidney Dis 53 5 (2009) 723-725
-
(2009)
Am J Kidney Dis
, vol.53
, Issue.5
, pp. 723-725
-
-
Wanner, C.1
-
14
-
-
0141678250
-
How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine
-
Herzog C.A. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 14 10 (2003) 2556-2572
-
(2003)
J Am Soc Nephrol
, vol.14
, Issue.10
, pp. 2556-2572
-
-
Herzog, C.A.1
-
15
-
-
0034962807
-
Cardiac arrest and sudden death in dialysis units
-
Karnik J.A., Young B.S., Lew N.L., et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 60 1 (2001) 350-357
-
(2001)
Kidney Int
, vol.60
, Issue.1
, pp. 350-357
-
-
Karnik, J.A.1
Young, B.S.2
Lew, N.L.3
-
16
-
-
0033782779
-
Cardiovascular risk in end-stage renal disease: vascular aspects
-
London G.M., Marchais S.J., Metivier F., and Guerin A.P. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant 15 suppl 5 (2000) 97-104
-
(2000)
Nephrol Dial Transplant
, vol.15
, Issue.SUPPL. 5
, pp. 97-104
-
-
London, G.M.1
Marchais, S.J.2
Metivier, F.3
Guerin, A.P.4
-
17
-
-
36549030340
-
Rosuvastatin in older patients with systolic heart failure
-
Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 22 (2007) 2248-2261
-
(2007)
N Engl J Med
, vol.357
, Issue.22
, pp. 2248-2261
-
-
Kjekshus, J.1
Apetrei, E.2
Barrios, V.3
|